Sana Biotechnology, Inc. (SANA)
| Market Cap | 730.44M -43.7% |
| Revenue (ttm) | n/a |
| Net Income | -211.82M |
| EPS | -0.76 |
| Shares Out | 299.36M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,819,942 |
| Open | 2.430 |
| Previous Close | 2.400 |
| Day's Range | 2.400 - 2.520 |
| 52-Week Range | 2.220 - 5.490 |
| Beta | 2.30 |
| Analysts | Strong Buy |
| Price Target | 8.43 (+245.49%) |
| Est. Earnings | Nov 17, 2026 |
About SANA
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company’s product pipeline includes UP421, a HIP-modified allogeneic primary islet cell product, which is in phase 1 clinical trial to treat type 1 diabetes; SC451, a HIP-modified, stem cell derived pancreatic islet cell therap... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for SANA stock is "Strong Buy." The 12-month stock price target is $8.43, which is an increase of 245.49% from the latest price.
News
Sana Biotechnology Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Two innovative platforms are advancing: a hypoimmune cell therapy for type 1 diabetes, with an IND and phase I/II trial planned by year-end, and an in vivo CAR T platform targeting cancer, with first-in-human data for SG293 expected in the next 12 months. Both programs aim for scalable, transformative therapies.
Sana Biotechnology Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The discussion highlighted progress toward a gene-edited, stem cell-derived islet therapy for type 1 diabetes, with IND clearance and a phase I trial expected this year. The in vivo CAR T platform is advancing, with clinical data anticipated in 2027. Strategic partnerships, manufacturing scalability, and capital allocation remain key priorities.
Sana Biotechnology Transcript: Citigroup’s Biopharma Back to School Summit 2026
Two major platforms are advancing: a hypoimmune cell therapy for type 1 diabetes nearing clinical trials, and an in vivo CAR T program targeting cancer, with first human data expected in 2027. Manufacturing scale-up, regulatory alignment, and site training are progressing, while the large market opportunity and cash runway are being strategically managed.
Sana Biotechnology Transcript: Wells Fargo 21st Annual Healthcare Conference
The session highlighted progress toward a one-time, gene-modified islet therapy for type 1 diabetes, with IND filing and phase I/II trials expected soon. In vivo CAR T programs are advancing, with initial trials in oncology and a focus on safety and scalability. Cash runway extends through mid-next year.
Sana Biotechnology Slides: Corporate presentation
Sana Biotechnology has posted slides in relation to its latest quarterly earnings report, which was published on September 8, 2026.
Did Sana Biotechnology, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...
Sana Biotechnology to Present at September 2026 Investor Conferences
SEATTLE, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webc...
Sana Biotechnology price target lowered to $6 from $7 at BofA
BofA lowered the firm’s price target on Sana Biotechnology (SANA) to $6 from $7 and keeps a Buy rating on the shares. The firm adjusted targets for several names in…
Sana Biotechnology reports Q2 EPS (13c), consensus (12c)
Reports Q2 cash, cash equivalents, and marketable securities of $160.5M, with expected cash runway into mid-2027. “Our team is executing on our goals of beginning clinical studies soon for both…
Sana Biotechnology Earnings release: Q2 2026
Sana Biotechnology released its Q2 2026 earnings on August 10, 2026, summarizing the period's financial results.
Sana Biotechnology Quarterly report: Q2 2026
Sana Biotechnology has published its Q2 2026 quarterly earnings report on August 10, 2026.
Sana Biotechnology Slides: Corporate presentation
Sana Biotechnology has posted slides in relation to its latest quarterly earnings report, which was published on August 10, 2026.
Sana Biotechnology announces publication of long-term diabetes data
Sana Biotechnology (SANA) announced that The New England Journal of Medicine has published a peer-reviewed letter to the editor by clinicians at Uppsala University Hospital highlighting 14-month follo...
Sana Biotechnology Announces Follow-On Publication in The New England Journal of Medicine (NEJM) Highlighting Groundbreaking Long-Term Data and Durability of Hypoimmune-Modified Islet Cell Transplantation Without Immunosuppression in Type 1 Diabetes
Peer-Reviewed Letter to the Editor Describes Updated Long-Term Findings Consistent with Initial Trial Data Featured in NEJM Article Published in 2025
Sana Biotechnology Announces Symposium Presentation at the European Association for the Study of Diabetes (EASD) Annual Meeting 2026
SEATTLE, July 01, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced a symposium presen...
Sana Biotechnology Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
The company is advancing two major platforms: a gene-modified islet therapy for type 1 diabetes aiming for a functional cure, and an in vivo CAR T platform with first-in-human trials planned this year. Key data readouts and manufacturing scale-up are expected over the next 12–18 months.
Sana Biotechnology Transcript: Jefferies Global Healthcare Conference 2026
Two advanced platforms—hypoimmune cell therapy for type 1 diabetes and in vivo CAR T—are set for clinical trials this year, with initial human data expected within 12 months. The type 1 diabetes program targets broad patient inclusion and aims for a functional cure, while the CAR T platform focuses on durable, targeted therapies for oncology and autoimmune diseases.
Sana Biotechnology to Present at June 2026 Investor Conferences
SEATTLE, May 27, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcas...
Sana Biotechnology Announces Sale of Approximately $69 Million of Shares Through its At-the-Market (ATM) Facility
SEATTLE , May 15, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it has sold a...
Sana Biotechnology presents preclinical data for in vivo CAR T cell therapy
Sana Biotechnology (SANA) announced the presentation of preclinical data demonstrating that a surrogate SG293, an in vivo CAR T cell therapy, achieved cell-specific delivery, robust and dose-dependent...
Sana Biotechnology Transcript: Bank of America Global Healthcare Conference 2026
The session highlighted a dual focus on engineered cell therapies for Type 1 diabetes and in vivo CAR-T, with significant progress in gene-modified islet transplantation and promising preclinical CAR-T data. Key milestones for SC451 and SG293 are expected within a year.
Sana Biotechnology Presents Preclinical Data for In Vivo CAR T Cell Therapy SG293 Surrogate Demonstrating Cell-Specific Delivery, Potent CAR T Cell Generation, and Deep B Cell Depletion in NHPs
SEATTLE, May 12, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced the presentation of...
Sana Biotechnology reports Q1 non-GAAP EPS (14c), consensus (15c)
Cash, cash equivalents, and marketable securities as of March 31, 2026 were $101.1M compared to $138.4M as of December 31, 2025. The decrease of $37.3M was primarily driven by cash…
Sana Biotechnology Reports First Quarter 2026 Financial Results and Business Updates
Announced strategic collaboration with Mayo Clinic, focused on improving care in type 1 diabetes and accelerating development of SC451
Sana Biotechnology Earnings release: Q1 2026
Sana Biotechnology released its Q1 2026 earnings on May 11, 2026, summarizing the period's financial results.